Oxford BioMedica has entered into an agreement to license its LentiVector technology to Biogen Idec for use in research activities
Oxford BioMedica will receive an upfront licence payment and an annual maintenance fee.
Further financial details were not disclosed.
LentiVector, a lentivirus-based system, is one of the most powerful technologies available for gene delivery to a wide range of cell and tissue types.
The technology has applications both in therapeutic products and drug discovery, as a tool for target validation and the creation of targeted disease models.
It has also been shown to enhance the efficiency of developing transgenic birds and mammals.
Oxford BioMedica has a comprehensive portfolio of US and European patents covering the LentiVector technology.
Oxford BioMedica's senior vice president commercial development, Peter Nolan, said: "We are delighted to add Biogen Idec to our list of licencees for the LentiVector technology".
"This agreement is a further demonstration of the technology's superiority and broad utility".
"We expect Oxford BioMedica's LentiVector technology to become the system of choice for safe and effective gene delivery in drug discovery and transgenics."
